首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   578篇
  免费   31篇
  国内免费   2篇
耳鼻咽喉   4篇
儿科学   18篇
妇产科学   63篇
基础医学   47篇
口腔科学   22篇
临床医学   62篇
内科学   68篇
皮肤病学   7篇
神经病学   30篇
特种医学   25篇
外科学   80篇
综合类   6篇
一般理论   3篇
预防医学   33篇
眼科学   2篇
药学   120篇
肿瘤学   21篇
  2023年   7篇
  2021年   5篇
  2020年   7篇
  2019年   16篇
  2018年   18篇
  2017年   11篇
  2016年   4篇
  2015年   10篇
  2014年   6篇
  2013年   24篇
  2012年   26篇
  2011年   23篇
  2010年   16篇
  2009年   12篇
  2008年   16篇
  2007年   35篇
  2006年   24篇
  2005年   22篇
  2004年   23篇
  2003年   24篇
  2002年   19篇
  2001年   21篇
  2000年   14篇
  1999年   17篇
  1998年   5篇
  1997年   5篇
  1996年   4篇
  1995年   3篇
  1993年   5篇
  1992年   11篇
  1991年   12篇
  1990年   11篇
  1989年   13篇
  1988年   16篇
  1987年   11篇
  1986年   14篇
  1985年   13篇
  1984年   14篇
  1983年   16篇
  1980年   3篇
  1979年   4篇
  1977年   3篇
  1976年   3篇
  1975年   7篇
  1974年   4篇
  1973年   7篇
  1972年   4篇
  1971年   3篇
  1966年   2篇
  1956年   5篇
排序方式: 共有611条查询结果,搜索用时 15 毫秒
21.
22.
OBJECTIVE: To examine the relationship between the pharmacodynamic and antipsoriatic effects of alefacept, a biologic agent that targets CD4+ and CD8+ memory T cells. DESIGN: Randomized, double-blind, placebo-controlled study of 3 parallel groups. SETTING: Fifty-one study centers. PATIENTS: Five hundred fifty-three patients with chronic plaque psoriasis. INTERVENTIONS: Patients were randomized (1:1:1) to 1 of the following 3 cohorts: alefacept, 7.5 mg, in both courses (cohort 1); alefacept, 7.5 mg, in the first course and placebo in the second course (cohort 2); or placebo in the first course and alefacept, 7.5 mg, in the second course (cohort 3). In each course, alefacept or placebo was administered by intravenous bolus once weekly for 12 weeks, followed by 12 weeks of observation. MAIN OUTCOME MEASURES: Circulating lymphocyte levels and the Psoriasis Area Severity Index. RESULTS: One or 2 courses of alefacept reduced CD4+ and CD8+ memory T-cell counts, while sparing the naive population. At 12 weeks after the last dose of alefacept in courses 1 and 2, 88% and 83% of patients, respectively, had CD4+ cell counts greater than the lower limit of normal. In course 1, alefacept-treated patients with the largest decreases in memory T-cell counts experienced the greatest reductions in disease activity (P<.001). The duration of clinical benefit seemed to be longer among patients who had the greatest reduction in CD4+ and CD8+ memory T-cell counts. CONCLUSIONS: One or 2 courses of intravenous alefacept reduced circulating memory T-cell counts while sparing the na?ve T-cell population. The reductions in memory T-cell counts were related to all measures of disease activity evaluated and the duration of response to therapy, suggesting that prolonged remissions of psoriasis can be attained with reduction of the pathogenic T-cell count.  相似文献   
23.
Mapping therapeutic response in a patient with malignant glioma   总被引:1,自引:0,他引:1  
Short-interval scanning of patients offers a detailed understanding of the natural progression of tumor tissue, as revealed through imaging markers such as contrast enhancement and edema, prior to therapy. Following treatment, short-interval scanning can also provide evidence of attenuation of growth rates. We present a longitudinal imaging study of a patient with glioblastoma multiforme (GBM) scanned 15 times in 104 days on a 3 T MR scanner. Images were analyzed independently by two automated algorithms capable of creating detailed maps of tumor changes as well as volumetric analysis. The algorithms, a nearest-neighbor-based tissue segmentation and a surface-modeling algorithm, tracked the patient's response to temozolomide, showing an attenuation of growth. The need for surrogate imaging end-points, of which growth rates are an example, is discussed. Further, the strengths of these algorithms, the insight gained by short-interval scanning, and the need for a better understanding of imaging markers are also described.  相似文献   
24.
Six experienced cocaine smokers (two men, four women) participated in an inpatient study to compare self-administration of smoked cocaine when either a $5 money or merchandise voucher was available as an alternative reinforcer. A six-trial choice procedure was used, with sessions consisting of (1) one sample trial, where participants received the cocaine dose and the alternative reinforcer available that day, and (2) five choice trials, where participants chose between the available cocaine dose and the alternative reinforcer. There were eight sessions: in separate sessions, each dose of cocaine (0, 12, 25, 50 mg) was paired with a money voucher and with a merchandise voucher. The choice to self-administer cocaine significantly increased with escalating cocaine doses, and significantly less cocaine was self-administered when money vouchers were available as compared to merchandise vouchers. These data demonstrate that money vouchers are a more effective alternative reinforcer than merchandise vouchers in cocaine abusers.  相似文献   
25.
The problem of forecasting the need and the cost for post-discharge skilled home nursing services is addressed by a simple statistical model. The model, assumptions, and simple calculations are described. Use of the model is illustrated with 7598 cancer patients and 2337 myocardial infarction patients. Simulation of the impact of changes in the health care delivery system toward greater and lesser severity of hospitalized patients is carried out. Two key projections illustrating the model's output are the number of patients with these diseases who will need care and the cost of that care.  相似文献   
26.
27.
28.
29.
Diastolic heart failure: a review and primary care perspective   总被引:4,自引:0,他引:4  
Previously the subject of much debate, there is now consensus that diastolic heart failure (DHF) represents a distinct form of heart failure. Epidemiologic data indicate that DHF is common. Indeed, there is evidence that, among elderly persons, DHF is more common than systolic heart failure (SHF). Like SHF, DHF is associated with significant morbidity, mortality, and cost; however, few clinical trials focusing on isolated DHF have been completed. Much of the treatment of DHF is based on current concepts of the pathophysiology of DHF, small clinical studies, and experience gained from treating patients with SHF. The diagnosis of DHF is clinical; data supporting the establishment of a diagnosis of DHF are limited. Differences exist in prognosis and treatment between diastolic and systolic heart failure. This article reviews diastolic heart failure with emphasis on evidence-based management, aimed at primary care physicians who routinely provide care to patients with DHF.  相似文献   
30.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号